Company directory
Directory
Directors
- Dr Charmaine Gittleson (Chair)
- Dr Gil Price
- Dr James Garner
Auditors
- Ernst & Young
- 8 Exhibition Street Melbourne, Victoria, 3000
Solicitors
- Minter Ellison
- Collins Arch, 447 Collins Street, Melbourne, Victoria, 3000
Company Secretary
- Mr Phillip Hains
- Joint Company Secretary: Alicia Mellors
Company
- Antisense Therapeutics Limited
- ACN 095 060 745
Share Register
- Boardroom Pty Limited
- Level 12, 225 George Street, Sydney, NSW 2000
- Telephone: 1300 737 760
- International: +61 2 9290 9600
Registered Office
- Level 1, 14 Wallace Avenue, Toorak, Victoria, 3142
- Telephone: +61 3 9827 8999
Australian Stock Exchange
- Antisense Therapeutics Limited shares are quoted on the Australian Stock Exchange.
- ASX Code: ANP
Principal Administrative Office & Mailing Address
- Level 1, 14 Wallace Avenue, Toorak, Victoria, 3142
- Telephone: +61 3 9827 8999
- Facsimile: +61 3 9859 7701
American Depository Receipts (ADR) Information
- Antisense Therapeutics Limited has established a Level 1 ADR Program. The ADRs trade in the US over-the-counter (OTC) market. Details are as follows:
- Ratio: 1 ADR = 20 ordinary shares
- Symbol: ATHJY
- CUSIP: 037183100
Bankers
- Commonwealth Bank of Australia, Melbourne, Victoria
Website
- www.antisense.com.au
What we're working on.
ATL1102
DMD is caused by a mutation in the muscle dystrophin gene leading to severe progressive muscle loss and premature death.
ATL1102
A disease in which the immune system eats away at the protective covering of nerves.
ATL1103
A disorder in adults in which the pituitary gland produces too much growth hormone.
Other indications
Limb-Girdle Muscular Dystrophy
A diseases that cause weakness and wasting of the muscles in the arms and legs.
Long Covid
A variety of new, returning or ongoing symptoms that people experience more than four weeks after getting COVID-19.
The people driving Antisense.
